Ⅰ期子宫内膜癌预后简易评分系统的建立

丁珊珊, 蒋鹏, 袁瑞, 胡琢瑛

PDF(1191 KB)
PDF(1191 KB)
重庆医科大学学报 ›› 2025, Vol. 50 ›› Issue (02) : 210-216. DOI: 10.13406/j.cnki.cyxb.003713
内膜癌变与辅助生殖技术

Ⅰ期子宫内膜癌预后简易评分系统的建立

作者信息 +

Establishment of a simple prognostic scoring system for stage Ⅰ endometrial carcinoma

Author information +
History +

摘要

目的 构建Ⅰ期子宫内膜癌预后简易评分系统为临床提供参考工具。 方法 回顾性收集2014年至2021年于重庆医科大学附属第一医院接受了手术治疗的Ⅰ期子宫内膜癌患者的病例资料,通过单因素及多因素Cox回归分析筛选与患者复发及死亡相关的影响因子。基于多因素分析结果,构建简易评分系统,利用受试者工作特征(receiver operating characteristic,ROC)曲线及其曲线下面积(area under the curve,AUC)比较评分系统和单一预测因子对患者预后的预测准确度。利用X-title软件确定评分系统的截值点并对患者进行风险分组,比较不同分组患者预后分布情况。 结果 多因素分析结果提示,患者年龄(复发:Wald χ2 =4.482,P=0.034;死亡:Wald χ2 =8.401,P=0.004)、病理分型(复发:Wald χ2 =6.692,P=0.010;死亡:Wald χ2 =4.222,P=0.040)、肌层浸润情况(复发:Wald χ2 =6.372,P=0.034;死亡:Waldχ2 =7.183,P=0.007)、淋巴脉管间隙侵犯(lymphovascular space invasion,LVSI)(复发:Wald χ2 =13.396,P<0.001;死亡:Wald χ2 =8.449,P=0.004)、雌激素受体(estrogen receptor,ER)表达(复发:Wald χ2 =7.679,P=0.006;死亡:Wald χ2 =8.532,P=0.003)及P53表达(复发:Wald χ2 =7.886,P=0.005;死亡:Wald χ2 =7.174,P=0.007)均是患者复发及死亡的影响因素。基于以上6个因素成功构建评估患者预后的简易评分系统,ROC曲线显示评分系统的AUC值大于单一预测因子。X-title软件确定了评分系统的截值点并自动将患者分为低风险组(0~1分)、中风险组(2~3分)及高风险组(4~6分),3组患者之间总体预后水平差异有统计学意义(P<0.001)。 结论 本研究构建的简易评分系统对Ⅰ期子宫内膜癌患者预后评估有一定价值。

Abstract

Objective To establish a simple prognostic scoring system for stage Ⅰ endometrial carcinoma,and to provide a reference tool for clinical practice. Methods A retrospective analysis was performed for the case data of the patients with stage Ⅰ endometrial carcinoma who received surgical treatment in The First Affiliated Hospital of Chongqing Medical University from 2014 to 2021,and univariate and multivariate Cox regression analyses were used to identify the influencing factors for recurrence and death. A simple scoring system was established based on the results of the multivariate analysis,and the receiver operating characteristic(ROC)curve and the area under the ROC curve(AUC)were used to compare the accuracy of the scoring system versus each single predictive factor in predicting the prognosis of patients. X-title software was used to determine the cut-off value of the scoring system and divide the patients into different risk groups,and then the prognosis distribution of patients was compared between groups. Results The multivariate analysis showed that age(recurrence:Wald χ2 =4.482,P=0.034;death:Wald χ2=8.401,P=0.004),pathological type(recurrence:Wald χ2 =6.692,P=0.010;death:Wald χ2 =4.222,P=0.040),myometrial invasion(recurrence:Wald χ2 =6.372,P=0.034;death:Wald χ2 =7.183,P=0.007),lymphovascular space invasion(recurrence:Wald χ2 =13.396,P<0.001;death:Wald χ2 =8.449,P=0.004),the expression of estrogen receptor(recurrence:Wald χ2 =7.679,P=0.006;death:Wald χ2 =8.532,P=0.003),and P53 expression(recurrence:Wald χ2 =7.886,P=0.005;death:Wald χ2 =7.174,P=0.007)were influencing factors for recurrence and death. A simple scoring system was successfully established for the prognosis of patients based on the above six factors,and the ROC curve analysis showed that the scoring system had a larger AUC than each predictive factor alone. The cut-off value of the scoring system was determined by X-title software,and the patients were divided into low-risk group(0-1 points),intermediate-risk group(2-3 points),and high-risk group(4-6 points); there was a significant difference in overall prognosis between the three groups(P<0.001). Conclusion The simple scoring system established in this study has a certain value in assessing the prognosis of patients with stage I endometrial carcinoma.

关键词

Ⅰ期 / 子宫内膜癌 / 预后 / 评分系统

Key words

stage I / endometrial carcinoma / prognosis / scoring system

中图分类号

R711.74

引用本文

导出引用
丁珊珊 , 蒋鹏 , 袁瑞 , . Ⅰ期子宫内膜癌预后简易评分系统的建立. 重庆医科大学学报. 2025, 50(02): 210-216 https://doi.org/10.13406/j.cnki.cyxb.003713
Ding Shanshan, Jiang Peng, Yuan Rui, et al. Establishment of a simple prognostic scoring system for stage Ⅰ endometrial carcinoma[J]. Journal of Chongqing Medical University. 2025, 50(02): 210-216 https://doi.org/10.13406/j.cnki.cyxb.003713

参考文献

1
Morice P Leary A Creutzberg C,et al. Endometrial cancer[J]. Lancet2016387(10023):1094-1108.
2
Salani R Nagel CI Drennen E,et al. Recurrence patterns and surveillance for patients with early stage endometrial cancer[J]. Gynecol Oncol2011123(2):205-207.
3
Siegel RL Miller KD Goding Sauer A,et al. Colorectal cancer statistics,2020[J]. CA Cancer J Clin202070(3):145-164.
4
Francis SR Ager BJ Do OA,et al. Recurrent early stage endometrial cancer:patterns of recurrence and results of salvage therapy[J]. Gynecol Oncol2019154(1):38-44.
5
Jiang P Huang J Deng Y,et al. Predicting recurrence in endometrial cancer based on a combination of classical parameters and immunohistochemical markers[J]. Cancer Manag Res202012:7395-7403.
6
Pecorelli S. Revised FIGO staging for carcinoma of the vulva,cervix,and endometrium[J]. Int J Gynaecol Obstet2009105(2):103-104.
7
Colombo N Creutzberg C Amant F,et al. ESMO-ESGO-ESTRO Consensus Conference on Endometrial Cancer:diagnosis,treatment and follow-up[J]. Ann Oncol201627(1):16-41.
8
Jiang P Jia MZ Hu J,et al. A nomogram model involving immunohistochemical markers for predicting the recurrence of stage I-II endometrial cancer[J]. Front Oncol202010:586081.
9
Jiang P Wang JY Gong CX,et al. A nomogram model for predicting recurrence of stage Ⅰ-Ⅲ endometrial cancer based on inflammation-immunity-nutrition score(IINS)and traditional classical predictors[J]. J Inflamm Res202215:3021-3037.
10
Jiang P Huang YZ Tu Y,et al. Combining clinicopathological parameters and molecular indicators to predict lymph node metastasis in endometrioid type endometrial adenocarcinoma[J]. Front Oncol202111:682925.
11
Takahashi K Yunokawa M Sasada S,et al. A novel prediction score for predicting the baseline risk of recurrence of stage I-II endometrial carcinoma[J]. J Gynecol Oncol201930(1):e8.
12
Jiang P Yuan R. Analysis of factors related to lymph node metastasis in early-stage type 1 endometrial cancer:verifying the clinical value of positive threshold of the immunohistochemical parameter Ki67[J]. Cancer Manag Res202113:6319-6328.
13
《乳腺癌雌、孕激素受体免疫组织化学检测指南》编写组. 乳腺癌雌、孕激素受体免疫组织化学检测指南[J]. 中华病理学杂志201544(4):237-239.
The Editorial Board of the “Guidelines for Immunohistochemical Detection of Estrogen and Progesterone Receptors in Breast Cancer”. Guidelines for immunohistochemical detection of estrogen and progesterone receptors in breast cancer[J]. Chin J Pathol201544(4):237-239.
14
Köbel M Ronnett BM Singh N,et al. Interpretation of P53 immunohistochemistry in endometrial carcinomas:toward increased reproducibility[J]. Int J Gynecol Pathol2019,38(Iss 1 Suppl 1):S123-S131.
15
朱梦秋,易倩琳,蒋 鹏. 低危子宫内膜癌淋巴结转移相关因素分析[J]. 第三军医大学学报202143(16):1581-1586.
Zhu MQ Yi QL Jiang P. Related factors for lymph node metastasis in low-risk endometrial cancer:analysis of 409 cases[J]. J Third Mil Med Univ202143(16):1581-1586.
16
Concin N Matias-Guiu X Vergote I,et al. ESGO/ESTRO/ESP guidelines for the management of patients with endometrial carcinoma[J]. Int J Gynecol Cancer202131(1):12-39.
17
Huang YZ Jiang P Kong W,et al. Comprehensive assessment of ERα,PR,Ki67,P53 to predict the risk of lymph node metastasis in low-risk endometrial cancer[J]. J Invest Surg202336(1):2152508.
18
Li N Jiang P Huang YZ,et al. Estrogen receptor- and progesterone receptor-positive thresholds in predicting the recurrence of early low-risk endometrial cancer[J]. Clin Med Insights Oncol202216:11795549221103200.
19
Raffone A Travaglino A Mascolo M,et al. TCGA molecular groups of endometrial cancer:Pooled data about prognosis[J]. Gynecol Oncol2019155(2):374-383.
20
Jia MZ Jiang P Hu J,et al. The optimal cut-off value of immunohistochemical parameter P53 for predicting recurrence of endometrial cancer[J]. Int J Gynaecol Obstet2021153(2):344-350.
21
León-Castillo A Gilvazquez E Nout R,et al. Clinicopathological and molecular characterisation of ‘multiple-classifier’ endometrial carcinomas[J]. J Pathol2020250(3):312-322.

基金

2022年重庆市科卫联合资助项目(2023MSXM116)

评论

PDF(1191 KB)

Accesses

Citation

Detail

段落导航
相关文章

/